Part 1: VP-315 3 Day Dosing/Week
VP-315-201
Phase 2 small_molecule completed
Quick answer
Part 1: VP-315 3 Day Dosing/Week for Basal Cell Carcinoma is a Phase 2 program (small_molecule) at Verrica Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Verrica Pharmaceuticals
- Indication
- Basal Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed